A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL+ adherent tumor cells

Journal of Immunological Methods

Volumn 217, Issue 1-2, 1998, Pages 71-78

  Böhm, Christian ^a   Hanski, Marie Luise ^a   Gratchev, Alexei ^a   Mann, Benno ^a   Moyer, Mary Pat ^b   Riecken, Ernst Otto ^a   Hanski, Christoph ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b InCell Corporation ^*  (United States)

Author keywords

Apoptosis; Fas ligand; JAM test; T cell; Tumor

Indexed keywords

COMPLEMENTARY DNA; DNA FRAGMENT; FAS ANTIGEN; FAS LIGAND; MONOCLONAL ANTIBODY;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CELL MEDIATED CYTOTOXICITY; COLON CARCINOMA; DNA DETERMINATION; EFFECTOR CELL; IMMUNOSURVEILLANCE; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTIGENS, CD95; APOPTOSIS; ARTIFACTS; CELL ADHESION; CELL SEPARATION; COLONIC NEOPLASMS; DNA FRAGMENTATION; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE REACTIONS; FAS LIGAND PROTEIN; HUMANS; IMMUNOLOGIC SURVEILLANCE; JURKAT CELLS; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; ULTRAFILTRATION;

EID: 0032144501     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(98)00100-8     Document Type: Article

References (30)

1. Allison J., Georgiou H.M., Strasser A., Vaux D.L. Transgenic expression of CD95 ligand on islet B cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA. 94:1997;3943.
2. Bellgrau D., Gold D., Selawry H., Moore A., Franzusoff A., Duke R.C. A role for CD95 ligand in preventing graft rejection. Nature. 377:1995;630.
3. Boon T., van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:1996;725.
4. Ehl S., Hoffmann-Rohrer U., Nagata S., Hengartner H., Zinkernagel R. Different susceptibility of cytotoxic T cells to CD 95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J. Immunol. 156:1996;2357.
5. French L.E., Hahne M., Viard I., Radlgruber G., Zanone R., Becker K., Müller C., Tschopp J. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic turnover. J. Cell Biol. 133:1996;335.
6. Glass A., Walsh C.M., Lynch D.H., Clark W.R. Regulation of the Fas lytic pathway in cloned CTL. J. Immunol. 156:1996;3638.
7. Green D.R., Ware C.F. Fas-ligand: privilege and peril. Proc. Natl. Acad. Sci. USA. 94:1997;5986.
8. Griffith T.S., Ferguson T.A. The role of FasL-induced apoptosis in immune privilege. Immunol. Today. 18:1997;240.
9. Hahne M., Rimoldi D., Schroeter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J.-C., Tschopp J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1996;1363.
10. Hahne M., Renno T., Schroeter M., Irmler M., French L., Bornand T., MacDonald H.R., Tschopp J. Activated B cells express functional Fas ligand. Eur. J. Immunol. 26:1996;721.
11. Kang S.M., Schneider D.B., Lin Z., Hanahan D., Dichek D.A., Stock P.G., Baekkeskov S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:1997;738.
12. Liles W.C., Kiener P.A., Ledbetter J.A., Aruffo A., Klebanoff S.J. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophiles. J. Exp. Med. 184:1996;429.
13. Lynch D.H., Ramsdell F., Alderson M.R. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today. 16:1995;569.
14. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Meth. 145:1991;185.
15. Montel A.H., Bochan M.R., Hobbs D.H., Lynch D.H., Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell. Immunol. 166:1995;236.
16. Moyer M.P., Manzano L.A., Meriman R.L., Stauffer J.S., Tanzer L.R. NCM-460, a normal human colon mucosal epithelial cell line. In Vitro Cell. Dev. Biol. Anim. 32:1996;315.
17. Nagata S. Apoptosis by death factor. Cell. 88:1997;355.
18. Niehans G.A., Brunner T., Frizelle S.P., Liston J.C., Salerno C.T., Knapp D.J., Green D.R., Kratzke R.A. Human lung carcinoma express Fas Ligand. Cancer Res. 57:1997;1007.
19. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas Ligand. J. Exp. Med. 184:1996;1075.
20. Rosenberg S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today. 18:1997;175.
21. Saas P., Walker P.R., Hahne M., Quiquerez A.-L., Schnuriger V., Perrin G., French L., van Meir E.G., de Tribolet N., Tschopp J., Dietrich P.-Y. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99:1997;1173.
22. Sabelko K.A., Kelly K.A., Nahm M.H., Cross A.H., Russell J.H. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159:1997;3096.
23. Seino K.-I., Kayagaki N., Okumura K., Yagita H. Antitumor effect of locally produced CD 95 ligand. Nat. Med. 3:1997;165.
24. Shiraki K., Tsuji N., Shioda T., Isselbacher K.J., Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA. 94:1997;6420.
25. Stauffer J.S., Manzano L.A., Balch G.C., Merriman R.L., Tanzer L.R., Moyer M.P. Development and characterization of normal colonic epithelial cell lines from normal mucosa of patients with colon cancer. Am. J. Surg. 169:1995;190.
26. Strand S., Hofmann W.J., Hug H., Müller M., Otto G., Strand D., Mariani S.M., Stremmel W., Krammer P.H., Galle P.R. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1996;1361.
27. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis family. Cell. 75:1993;1169.
28. Suss G., Shortman K. A subclass of dendritic cells kills CD4 T cells via Fas/Fas ligand-induced apoptosis. J. Exp. Med. 183:1996;1789.
29. Walker P.R., Saas P., Dietrich P.-Y. Role of Fas ligand (CD95L) in immune escape. J. Immunol. 158:1997;4521.
30. Zeytun A., Hassuneh M., Nagarkatti M., Nagarkatti P.S. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood. 90:1997;1952.